<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00485589</url>
  </required_header>
  <id_info>
    <org_study_id>ACT3984g</org_study_id>
    <secondary_id>WA20497</secondary_id>
    <nct_id>NCT00485589</nct_id>
  </id_info>
  <brief_title>A Study of Ocrelizumab in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Are Naive to Methotrexate (FILM)</brief_title>
  <acronym>FILM</acronym>
  <official_title>A Randomized, Double-Blind, Parallel Group, International Study to Evaluate the Safety and Efficacy of Ocrelizumab in Combination With Methotrexate (MTX) Compared to MTX Alone in Methotrexate- Naive Patients With Active Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Genentech, Inc.</source>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy and safety of ocrelizumab, compared with placebo, in
      combination with methotrexate in patients with active rheumatoid arthritis who are naive to
      methotrexate. Patients will be randomized to receive placebo, ocrelizumab 200mg i.v. or
      ocrelizumab 500mg i.v. on Days 1 and 15. Repeat courses of i.v. treatment will be
      administered at weeks 24, 52 and 76. All patients will receive concomitant methotrexate (7.5
      mg escalating to 20mg p.o. weekly). The anticipated time on study treatment is 2+ years, and
      the target sample size is 500+ individuals.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Based on analysis of results and consideration of available treatments, the overall benefit to
    risk profile of ocrelizumab was not favorable in RA.
  </why_stopped>
  <start_date type="Actual">June 2007</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in the modified total Sharp score</measure>
    <time_frame>Week 52</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Health Assessments Questionnaire - Disability Index (HAQ-DI) score</measure>
    <time_frame>Week 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with a major clinical response</measure>
    <time_frame>Weeks 52 and 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving Disease Activity Score (DAS28) remission</measure>
    <time_frame>Weeks 24, 52, and 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in DAS28 from baseline</measure>
    <time_frame>Weeks 24, 52, and 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EULAR response rates</measure>
    <time_frame>Weeks 24, 52, and 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving an ACR20/ACR50/ACR70/ACR90 response</measure>
    <time_frame>Weeks 24, 52, and 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with a reduction of at least 0.25 units in the HAQ-DI score from baseline</measure>
    <time_frame>Weeks 24 and 52</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">613</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <description>Oral repeating dose</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ocrelizumab</intervention_name>
    <description>Intravenous repeating dose</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Intravenous repeating dose</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Age â‰¥ 18

          -  Rheumatoid arthritis for 3 months-5 years

          -  Naive to methotrexate

          -  If receiving steroids or NSAIDs, must be on a stable dose for 4 weeks prior to
             baseline

        Exclusion criteria:

          -  Rheumatic autoimmune disease or inflammatory joint disease other than RA

          -  Prior receipt of any biologic therapy for RA

          -  Concurrent treatment with any DMARD
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wolfgang Dummer, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Genentech, Inc.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 11, 2007</study_first_submitted>
  <study_first_submitted_qc>June 11, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2007</study_first_posted>
  <disposition_first_submitted>June 28, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>June 28, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 4, 2013</disposition_first_posted>
  <last_update_submitted>May 10, 2017</last_update_submitted>
  <last_update_submitted_qc>May 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FILM</keyword>
  <keyword>RA</keyword>
  <keyword>anti-CD20</keyword>
  <keyword>CD20</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

